Long non-coding RNAs in psoriatic and healthy skin

In this study, we used RNA-sequencing to profile the long non-coding RNA (lncRNA) transcriptome in lesional skin from psoriasis patients before (PP) and after treatment (PT) with adalimumab and in normal skin from healthy individuals (NN). For this we sequenced total RNA from 18 psoriasis patients (before and after treatment) and 16 healthy controls. We created our own reference set of long non-coding RNAs by merging three long non-coding RNA reference data sets. The combined reference had 67,157 lncRNA transcripts with no overlaps. We identified differential expression of 971 lncRNAs between PP and NN, 157 between PP and PT, and 377 between PT and NN. Based on differentially expressed (DE) lncRNAs between PP and NN, we identified a molecular lncRNA signature that distinguishes psoriatic skin from healthy skin . Overall design: We recruited 18 psoriatic patients in our study. We took 5 mm punch biopsies from the edge of a psoriatic plaque before treatment and after one month of treatment with adalimumab. The mean improvement in the PASI over this time period was 53.1%. We obtained sixteen normal skin samples (N=16) from healthy control surgical discard specimens.

本研究采用RNA测序技术，对银屑病患者接受阿达木单抗（adalimumab）治疗前皮损皮肤（PP组）、治疗后皮损皮肤（PT组），以及健康个体正常皮肤（NN组）的长链非编码RNA（long non-coding RNA，lncRNA）转录组进行了表征分析。本研究共对18名银屑病患者（治疗前后）及16名健康对照的总RNA进行了测序。本研究通过整合3组长链非编码RNA参考数据集，构建了专属的lncRNA参考集，整合后的参考集共包含67157条无重叠的lncRNA转录本。本研究共鉴定出PP组与NN组间差异表达的lncRNA共971条，PP组与PT组间共157条，PT组与NN组间共377条。基于PP组与NN组间的差异表达（differentially expressed，DE）lncRNA，本研究鉴定出可区分银屑病皮损皮肤与健康皮肤的lncRNA分子标签。实验设计：本研究共招募18名银屑病患者，分别于阿达木单抗治疗前及接受1个月治疗后，从银屑病斑块边缘采集5mm直径的穿刺活检样本。此期间受试者的银屑病面积与严重程度指数（Psoriasis Area and Severity Index，PASI）平均改善率达53.1%。本研究从健康对照的外科废弃标本中获取了16份正常皮肤样本（N=16）。